Flag of the European Union EU Clinical Trials Register Help

Clinical trials for hodgkin's lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44257   clinical trials with a EudraCT protocol, of which   7344   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    698 result(s) found for: hodgkin's lymphoma. Displaying page 1 of 35.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-003369-17 Sponsor Protocol Number: 05/13 Start Date*: 2005-02-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A phase II Multi-Dose Study of SGN-30 anti-CD30 mAb in Patients with Refractory or Recurrent Hodgkin s Disease or Anaplstic Large Cell Lymphoma
    Medical condition: Patients with Refractory or Recurrent Hodgkin s Disease or Anaplastic Large Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025319 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001385-38 Sponsor Protocol Number: WIN-HYPO2021 Start Date*: 2021-08-18
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODG...
    Medical condition: medulloblastoma, Hodgkin and non-Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002251-26 Sponsor Protocol Number: CL1-078454-018 Start Date*: 2014-09-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study
    Medical condition: Hodgkin's Disease (HD) , Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008993 Chronic lymphoid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001888-40 Sponsor Protocol Number: DEP NHL-P 001.A Start Date*: 2006-07-24
    Sponsor Name:Mundipharma Research Ltd.
    Full Title: A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with agg...
    Medical condition: Prophylaxis of CNS relapse in adult patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10029547 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-007091-41 Sponsor Protocol Number: DSC/07/2357/31 Start Date*: 2008-01-19
    Sponsor Name:ITALFARMACO
    Full Title: Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma Patients
    Medical condition: Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020206 Hodgkin's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003128-30 Sponsor Protocol Number: Uni-Koeln-1776 Start Date*: 2016-05-19
    Sponsor Name:University of Cologne
    Full Title: Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
    Medical condition: relapsed lymphocyte-predominant Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000256-18 Sponsor Protocol Number: CRAD001N2202 Start Date*: 2013-07-25
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A single-arm, open label, multi-center phase II study investigating oral everolimus tablets with dose titration in pediatric patients with relapsed or refractory Hodgkin lymphoma
    Medical condition: relapsed or refractory Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002141-37 Sponsor Protocol Number: HOVON 80 NHL Start Date*: 2006-09-28
    Sponsor Name:HOVON foundation
    Full Title: Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-ce...
    Medical condition: relapsed B cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-004908-37 Sponsor Protocol Number: IRIS Start Date*: 2011-10-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Phase II study on activity and tolerability of intralesional rituximab in relapsed or refractory patients affected by indolentCD-20 positive lymphoma of conjuntiva; evaluation of activity of adding...
    Medical condition: indolent CD-20 positive lymphoma of conjunctiva
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001666-32 Sponsor Protocol Number: APM4083g Start Date*: 2007-12-05
    Sponsor Name:Genentech Inc
    Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULA...
    Medical condition: Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029593 Non-Hodgkin's lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003824-12 Sponsor Protocol Number: ProRom Start Date*: 2011-10-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Pilot phase II trial on safety and activity of secondary prophylaxis with Romiplostim in patients with non-Hodgkin lymphoma and chemotherapy-induced throm-bocytopenia
    Medical condition: chemotherapy-induced thrombocytopenia in patients affected by non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002626-37 Sponsor Protocol Number: Uni-Koeln-2854 Start Date*: 2017-03-10
    Sponsor Name:University of Cologne
    Full Title: Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial
    Medical condition: Improvement of first-line treatment for early-stage unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab in combincation with a truncated standard chemotherapy (AVD).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013839-37 Sponsor Protocol Number: HD0803 Start Date*: 2010-03-30
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: A phase II multi-centre study of MBVD in elderly and/or cardiopathic patients affected by Hodgkin s lymphoma (HL).
    Medical condition: elderly and/or cardiopathic patients affected by Hodgkin s lymphoma (HL).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025319 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017603-28 Sponsor Protocol Number: PG-APRE1 Start Date*: 2010-02-03
    Sponsor Name:AZIENDA OSPEDALIERA DI PERUGIA
    Full Title: Aprepitant for prevention of acute and delayed nausea and vomiting: a phase III, double-blind, randomized, palcebo-controlled trial in patients receiving a high-emetogenic dose of cyclophosphamide ...
    Medical condition: Multiple myeloma, Hodgkin lymphoma, Non-Hodgkin lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025319 HLGT
    9.1 10025322 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000689-21 Sponsor Protocol Number: MOZ008-08 Start Date*: 2008-07-21
    Sponsor Name:Genzyme Europe BV
    Full Title: Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple M...
    Medical condition: Mobilisation of peripheral blood stem cells prior to autologous stem cell transplantation in patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10020206 Hodgkin's disease LLT
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016588-12 Sponsor Protocol Number: RV-HL-GOTEL-440 Start Date*: 2010-09-29
    Sponsor Name:Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL)
    Full Title: ENSAYO FASE II PARA VALORAR LA COMBINACIÓN DE LENALIDOMIDA CON DOSIS METRONÓMICAS DE CICLOFOSFAMIDA EN PACIENTES CON LINFOMA DE HODGKIN CLÁSICO REFRACTARIO O EN RECAÍDA
    Medical condition: Linfoma de Hodgkin clásico recidivado o refractario.
    Disease: Version SOC Term Classification Code Term Level
    11 10025319 Linfomas de la enfermedad de Hodgkin HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005082-21 Sponsor Protocol Number: Uni-Koeln-1491 Start Date*: 2012-09-25
    Sponsor Name:University of Cologne
    Full Title: Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma
    Medical condition: newly diagnosed advanced classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002684-14 Sponsor Protocol Number: IIL HD 0801 Start Date*: 2008-10-20
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: Early salvage with high dose chemotherapy and stem cell transplantation in advanced stage Hodgkin’s lymphoma patients with positive positron emission tomography after two courses of ABVD (PET-2 pos...
    Medical condition: HODGKIN LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020205 Hodgins LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000049-36 Sponsor Protocol Number: DSC/07/2357/26 Start Date*: 2007-05-07
    Sponsor Name:ITALFARMACO
    Full Title: Phase II study of the histone-deacetylase inhibitor ITF2357 in very high-risk relapsed/refractory Hodgkin's lymphoma patients
    Medical condition: Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020206 Hodgkin's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020363-21 Sponsor Protocol Number: SGN35-010 Start Date*: 2010-11-09
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma
    Medical condition: Patients who were on the placebo arm and experienced progression of HL while participating in the SGN35-005 clinical study
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA